蜀羊泉散加味联合同步放化疗对中晚期宫颈癌患者血清CYFRA21-1、SCC-Ag、TK1、HE4的影响  

Effects of Modified Shuyangquan Powder(蜀羊泉散加味) Combined with ConcurrentR adiotherapy and Chemotherapy on Serum CYFRA21-1,SCC-Ag,TK1 and HE4 in Patients with Advanced Cervical Cancer

作　　者：姚爱华 宋辉 蒋寅 YAO Aihua;SONG Hui;JIANG Yin(Tongling Municipal Hospital,Tongling 244000,Anhui,China)

机构地区：[1]铜陵市立医院,安徽铜陵244000

出　　处：《中华中医药学刊》2022年第11期238-241,共4页Chinese Archives of Traditional Chinese Medicine

基　　金：安徽省自然科学基金(1508085MH198)。

摘　　要：目的 观察蜀羊泉散加味联合同步放化疗对中晚期宫颈癌患者疗效、血清指标及生存的影响。方法 选取2015年1月—2019年12月在医院就诊的中晚期宫颈癌患者120例,采用随机数字表法分为观察组和对照组各60例,对照组应用常规放化疗方法,观察组应用蜀羊泉散加味联合同步放化疗治疗,治疗4个疗程后进行疗效评价,比较两组患者治疗前后卡氏生活质量(karnofsky performance status, KPS)评分、疼痛视觉模拟(visual analogue scale, VAS)评分及血清细胞角质蛋白19片段抗原21-1(cytokeratin 19 fragment antigen 21-1,CYFRA21-1)、鳞状上皮细胞癌抗原(squamous cell carcinoma antigen, SCC-Ag)、胸苷激酶1(thymidine kinase 1,TK1)、人附睾蛋白4(human epididymis protein 4,HE4)水平,并比较不良反应和生存情况。结果 治疗后,观察组总有效率及生存率显著高于对照组(P<0.05),恶心呕吐、白细胞减少及血小板下降发生率显著低于对照组(P<0.05);治疗后,两组VAS评分及血清CYFRA21-1、SCC-Ag、TK1、HE4水平均较治疗前降低,KPS评分较治疗前升高(P<0.05);治疗后,观察组血清CYFRA21-1、SCC-Ag、TK1、HE4水平均低于对照组,KPS评分高于对照组(P<0.05)。结论 蜀羊泉散加味联合同步放化疗对中晚期宫颈癌疗效显著,可有效减轻患者疼痛,提高患者生存率及生活质量,降低血清CYFRA21-1、SCC-Ag、TK1、HE4水平,具有一定临床应用价值。Objective To observe the clinical effect of Modified Shuyangquan Powder(蜀羊泉散加味)combined with concurrent radiotherapy and chemotherapy on the efficacy,serum indexes and survival of patients with mid-late cervical cancer.Methods A total of 120 patients with mid-late cervical cancer who were treated in the hospital from January 2015 to December 2019 were randomly divided into the observation group and the control group,with 60 cases in each group.The control group was treated with conventional radiotherapy and chemotherapy,and the observation group was treated with Modified Shuyangquan Powder and concurrent radiotherapy and chemotherapy.The curative effect was evaluated after 4 courses of treatment.The Karnofsky performance status(KPS)score,visual analogue scale(VAS)score and the levels of serum cytokeratin 19 fragment antigen 21-1(CYFRA21-1),squamous cell carcinoma antigen(SCC-Ag),thymidine kinase 1(TK1)and human epididymis protein 4(HE4)were compared between the two groups before and after treatment and adverse reactions and survival were compared.Results After treatment,the total effective rate and survival rate of the observation group were significantly higher than those of the control group(P<0.05).The incidences of nausea and vomiting,leucopenia and thrombocytopenia were significantly lower than those of the control group(P<0.05).After treatment,VAS score and serum levels of CYFRA21-1,SCC-Ag,TK1 and HE4 in the two groups were lower than those before treatment,and KPS score was higher than that before treatment(P<0.05).After treatment,the levels of serum CYFRA21-1,SCC-Ag,TK1 and HE4 in the observation group were lower than those in the control group,and the KPS score was higher than that in the control group(P<0.05).Conclusions The combination of Modified Shuyangquan Powder and concurrent radiotherapy and chemotherapy has a significant effect on mid-late cervical cancer,which can effectively reduce relieve the pain,improve the survival rate and quality of life of patients,reduce the levels of serum

关 键 词：蜀羊泉散加味 放化疗 中晚期宫颈癌 细胞角质蛋白19片段抗原21-1 鳞状上皮细胞癌抗原 胸苷激酶1 人附睾蛋白4 

分 类 号：R273.373.3[医药卫生—中西医结合]